Related Experiment Video

Updated: Jun 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Bevacizumab in the treatment of HER2-negative breast cancer

Vito Lorusso1

  • 1Oncologic Institute, Vito Fazzi Hospital, Lecce, Italy.

Biologics : Targets & Therapy
|August 27, 2009
PubMed

Insights

Bevacizumab, an anti-vascular endothelial growth factor (VEGF) therapy, shows promise in treating metastatic breast cancer (MBC). Combination with taxanes improves progression-free survival in first-line MBC treatment.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Angiogenesis is crucial for breast cancer progression.
  • Anti-VEGF therapies offer a potential treatment strategy for metastatic breast cancer (MBC).

Purpose of the Study:

  • To evaluate the efficacy of bevacizumab, a VEGF inhibitor, in treating metastatic breast cancer.
  • To assess bevacizumab's role in combination therapies for MBC.

Main Methods:

  • Review of preclinical and clinical trials, including Phase 1/2 and Phase 3 studies.
  • Analysis of bevacizumab's effects alone and in combination with cytotoxic agents like capecitabine and taxanes.

Main Results:

  • Bevacizumab demonstrated antitumor effects in MBC, particularly in HER2-negative tumors.
  • Phase 3 trials showed improved response rates but not survival with bevacizumab and capecitabine in pre-treated patients.
  • Phase 2 trials indicated improved progression-free survival when bevacizumab was combined with weekly paclitaxel or 3-weekly docetaxel in first-line MBC.

Conclusions:

  • Bevacizumab combined with taxanes represents a highly effective first-line treatment for MBC.
  • Further investigation into bevacizumab's use in neoadjuvant or adjuvant settings is warranted.
Keywords:
HER2HER2-negative breast cancerbevacizumabbreast cancer

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.